<DOC>
	<DOC>NCT00919282</DOC>
	<brief_summary>The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).</brief_summary>
	<brief_title>Gemcitabine (GFF) in Patients With Pancreatic Cancer</brief_title>
	<detailed_description>This open-label, multi center phase II study was conducted to investigate the efficacy and safety of the combination of 5-Fluorouracil (5-FU)/folinic acid (FA) plus gemcitabine (GFF) in patients (pts) with advanced pancreatic cancer (APC). We consequently started this study after completing the phase I trial accomplished by our CONKO- study group.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>histological proved pancreatic cancer inoperable disease informed consent adequate bone marrow reserve under 18 years brain metastasis lactating woman life expectancy under 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>combination</keyword>
</DOC>